دورية أكاديمية
Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus : A Post Hoc Analysis
| العنوان: | Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus : A Post Hoc Analysis |
|---|---|
| المؤلفون: | Ahrén, Bo, Galstyan, Gagik, Gautier, Jean Francois, Giorgino, Francesco, Gomez-Peralta, Fernando, Krebs, Michael, Nikonova, Elena, Stager, William, Vargas-Uricoechea, Hernando |
| المصدر: | Diabetes Therapy; 7(3), pp 583-590 (2016) ; ISSN: 1869-6953 |
| بيانات النشر: | Springer |
| سنة النشر: | 2016 |
| المجموعة: | Lund University Publications (LUP) |
| مصطلحات موضوعية: | Endocrinology and Diabetes, Glucagon, Glucagon-like peptide-1 receptor agonist, Glycemic control, Lixisenatide, Prandial, Type 2 diabetes mellitus |
| الوصف: | Introduction: The extent to which postprandial glucagon reductions contribute to lowering of postprandial glucose in patients with type 2 diabetes mellitus (T2DM) is currently unknown. The aim of this analysis was to determine whether a reduction in postprandial glucagon following treatment with the glucagon-like peptide-1 receptor agonist lixisenatide correlates with a reduction in postprandial glucose and glycated hemoglobin (HbA1c) in patients with T2DM. Methods: A post hoc analysis was performed on pooled data from the modified intent-to-treat populations of two lixisenatide Phase 3 trials: GetGoal-M (lixisenatide versus placebo as add-on to metformin) and GetGoal-S (lixisenatide versus placebo as add-on to sulfonylurea [SU] ± metformin). Glucagon levels were assessed 2 h after a standardized meal test performed at baseline and Week 24 and were examined for correlation with changes in 2-h postprandial glucose and HbA1c. Results: Lixisenatide reduced 2-h postprandial glucagon at Week 24 compared with placebo (P < 0.00001). The mean change in postprandial glucagon significantly correlated with reductions in postprandial glucose (P < 0.00001) and HbA1c (P < 0.00001). Conclusion: A reduction in postprandial glucagon following lixisenatide administration correlated with a decrease in postprandial glucose and HbA1c in patients with T2DM insufficiently controlled on metformin and/or SU. This suggests that lowering of postprandial glucagon contributes to the overall glycemic improvement observed with lixisenatide. Funding: Sanofi. Clinical Trial Numbers: NCT00712673 (GetGoal-M) and NCT00713830 (GetGoal-S). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://lup.lub.lu.se/record/991ff9cc-bb35-467e-96e0-a9d6601c78f7Test; http://dx.doi.org/10.1007/s13300-016-0179-6Test; pmid:27319011; wos:000382882000017; scopus:84986201026 |
| DOI: | 10.1007/s13300-016-0179-6 |
| الإتاحة: | https://doi.org/10.1007/s13300-016-0179-6Test https://lup.lub.lu.se/record/991ff9cc-bb35-467e-96e0-a9d6601c78f7Test |
| رقم الانضمام: | edsbas.B0593843 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s13300-016-0179-6 |
|---|